A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis

(2021) Andreas E. Kremer et al.   LIVER INTERNATIONAL

Goals of Treatment for Improved Survival in Primary Biliary Cholangitis

(2020) Carla F. Murillo Perez et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Primary biliary cholangitis

(2020) Ana Lleo et al.   LANCET

Beyond Biochemical Responses, Use of Histologic Staging to Predict Outcomes of Patients With Primary Biliary Cholangitis

(2019) Aliya F. Gulamhusein et al.   Clinical Gastroenterology and Hepatology

Management of Chronic Hepatic Itch

(2018) Miriam M. Düll et al.   DERMATOLOGIC CLINICS

A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis

(2018) Christophe Corpechot et al.   NEW ENGLAND JOURNAL OF MEDICINE

The ascending pathophysiology of cholestatic liver disease

(2017) Peter L.M. Jansen et al.   HEPATOLOGY

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis

(2017) Gideon M. Hirschfield et al.   JOURNAL OF HEPATOLOGY

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

(2016) Frederik Nevens et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid

(2015) Gideon M. Hirschfield et al.   GASTROENTEROLOGY

Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy

(2015) Willem J. Lammers et al.   GASTROENTEROLOGY

The immunogenetics of primary biliary cirrhosis: A comprehensive review

(2015) G.J. Webb et al.   JOURNAL OF AUTOIMMUNITY

Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study

(2014) Willem J. Lammers et al.   GASTROENTEROLOGY

Liver X receptor β and peroxisome proliferator-activated receptor δ regulate cholesterol transport in murine cholangiocytes

(2012) Xuefeng Xia et al.   HEPATOLOGY

Protection from liver fibrosis by a peroxisome proliferator-activated receptor   agonist

(2012) K. Iwaisako et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome

(2011) Christophe Corpechot et al.   JOURNAL OF HEPATOLOGY

Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis

(2010) Teru Kumagi et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Improved Prognosis of Patients With Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic Acid

(2009) Edith M.M. Kuiper et al.   GASTROENTEROLOGY

Peroxisome proliferator-activated receptor delta activation leads to increased transintestinal cholesterol efflux

(2009) Carlos L. J. Vrins et al.   JOURNAL OF LIPID RESEARCH

Alternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin Resistance

(2008) Justin I. Odegaard et al.   Cell Metabolism

Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis

(2008) Christophe Corpechot et al.   HEPATOLOGY